Amyloid-b (Ab) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Ab levels in the cerebrospinal fluid (CSF) during the development of Alzheimer's disease (AD), the link between the alternation of Ab level in the blood and the progress of the disorder is still controversial. Here, we report a direct correlation of Ab(1-42) levels between CSF and plasma in AD mouse model. We injected monomeric Ab(1-42) directly into the intracerebroventricular (ICV) region of normal adult mouse brains to induce AD-like phenotypes. Using sandwich enzyme-linked immunosorbent assays, we observed proportional elevation of Ab(1-42) levels in both CSF and plasma in a dose-dependent manner. Our findings that plasma Ab(1-42) reflects the condition of CSF Ab(1-42) warrant further investigation as a biomarker for the blood diagnosis of AD.
B
lood Ab is an attractive biomarker of AD for the well-characterized efflux mechanism to pass the bloodbrain barrier (BBB); the low-density lipoprotein receptor-related protein-1 in BBB allows brain Ab to be actively transported to blood 1, 2 . Thus, quantification of plasma Ab is considered as an emerging diagnostic tool for AD 2, 3 . Indeed, recent clinical studies have reported association of reduced Ab(1-42) level in plasma with cognitive decline and risk development of AD 1, [4] [5] [6] . However, contrasting cross-sectional cases have claimed the medical use of blood-based Ab measurements to be debatable [7] [8] [9] [10] ; heterogeneity of patient groups and assay protocols may have contributed to the provocative results. Dissimilar aspects of plasma Ab analysis in varied subjects are also observed in amyloid precursor protein (APP) transgenic mouse models. Studies of two APP mouse models with different point mutations argue that the surrogate scale of plasma Ab reflected Ab abnormalities in CSF of AD brains 11, 12 . During the plaque formation, PDAPP mice, with Indiana APP mutation, lose the correlation between plasma and CSF Ab; meanwhile, Tg2576 mice, with Swedish APP mutation, show a significant and simultaneous decrease in both CSF and plasma Ab. Thus, it is critical to proceed a clinical investigation of plasma Ab for its validity as a surrogate marker of risk development of AD under controlled milieu. The Abinfusion mouse model offers benefits to minimize neuropathological factors of AD over the use of APP overexpressing transgenic rodents impairments in this animal model before studying the surrogate role of plasma Ab to predict at-risk AD subjects. We performed Y-maze tasks to assess working memory alternations by measuring spontaneous alternation behaviors (Figure 1a,b) 14 . In a threearmed Y-shaped maze, the subjected animal must remember the order of arm entries, and the superior alternation rate indicates the better sustained cognition. Working memory ability and locomotion levels were determined as percent alternation and total arm entries, respectively, on the Y-maze. We found that single ICV injection of Ab(1-42) monomers (0.25 nmole) significantly reduced cognitive behavioral performance on the Y-maze task when compared to vehicle-injected normal adult ICR mice (Figure 1c,d) , without affecting locomotion levels.
Comparison of Ab(1-42) levels in CSF and plasma. In AD brains, alternations of CSF Ab(1-42) levels were reversely correlated with progressive deposition of insoluble Ab-plaques and development of AD 15, 16 . To mimic alternations of CSF Ab levels in AD, we injected diverse concentrations of Ab(1-42) (0, 0.25, 0.5, 2 and 4 nmole) in parallel into the ICV region of normal adult ICR mice (male, n 5 5 per group). We collected CSF by laboratory-produced capillary tubes with tapered tips as previously described 17 . In sandwich-ELISA utilizing two anti-Ab antibodies with different epitopes, we confirmed that CSF Ab(1-42) levels directly replicated dosedependency of the injected peptides ( Figure 2 and Table 1 ) (Kruskal-Wallis test, P 5 0.0076). After the CSF collection, we transferred blood from vena cava directly to EDTA tubes and isolated plasma. In order to assess validity of plasma Ab as an AD surrogate biomarker, we measured Ab(1-42) levels in plasma samples of mice subjected to aforementioned CSF studies by the sandwich-ELISA. We found that the levels of plasma Ab(1-42) correspondingly elevated as we increased the amount of ICVinjected Ab(1-42) monomers in mice ( Figure 3 and Table 1 ) (Kruskal-Wallis test, P 5 0.0008). Collectively, these results indicated that plasma Ab(1-42) levels acutely reflected alternations of the CSF Ab(1-42) concentration ( Figure 4 ).
Discussion
In this study, we compared Ab(1-42) levels in CSF and plasma of atrisk AD model mice. We artificially raised amounts of Ab monomers in CSF of normal adult ICR mice by ICV injection and observed the corresponding increase of Ab(1-42) levels in plasma. Our results correspond to two conflicting studies using APP transgenic mouse models; these studies conditionally agree on the significant association between CSF and plasma Ab before the development of plaque deposition 11, 12 . Given that these transgenic mice have different genetic backgrounds and mutations, asymmetrical aspects of CSF-plasma Ab ratio in these studies indicate strong needs for blood biomarker investigations to adopt Ab specific animal models without additional neuropathological factors. Thus, we restricted neuropathology of subjected animals to abnormal increase of brain Ab and measured Ab levels considering the half-time for brain efflux of the peptide 18 . As we intended to create Ab-focused environment in mice, our study lacks many pathophysiological mechanisms in AD such as chronic processing and clearance of Ab. Thus, additional studies are warranted to determine whether the correlation between plasma and CSF Ab will translate into AD diagnosis within diverse neuropathological conditions.
Our present study provides assurance that the Ab in plasma is an important target candidate for AD diagnosis. The concept of Ab blood test is an unprecedentedly convenient tool for both physicians and patients to predict the pathological progress of AD. However, reliable measurements of plasma Ab by overcoming cross-sectional diversity will subsequently confront the challenge as a valid surrogate biomarker for neurodegeneration of AD. Quantification of abnormal Ab processing and clearance in the brain has been a major diagnostic method of AD. During the investigation of Ab neuroimaging tracers, needs for additional biomarkers have been raised due to significant cases of non-demented, Ab-positive individuals 19 . Thus, clinical evidences at present strongly support the view that diagnosis of AD requires detection of both Ab and tau abnormalities 20 . As Ab deposition timely leads to hyperphosphorylated tau aggregation followed by cerebral atrophy, the former is considered useful for early diagnosis and the latter for neurodegeneration 15 . Given that plasma Ab levels would limitedly reflect the status of Ab abnormality in the central nervous system, further challenges of AD blood tests would be investigating additional blood surrogate markers of neurodegeneration 21 . Present findings propose that blood-based Ab quantification should be investigated further as a possible surrogate biomarker for AD diagnosis. were added DMSO. We synthesized Ab(1-42) on 0.25 mmole of Wang resin with 1.1 mmole of every amino acid except for the first amino acid. First amino acid requires 2.2 mmole for symmetric anhydride activation. Before synthesis, resin should be swollen in DMF for an hour. For the symmetric anhydride activation, 2.2 mmole of first amino acid, Fmoc-Ala-OH, was dissolved in DMF (2 mL) and DIC (156 mL) was added to amino acid dissolved solution. Until the clear DMF solution became unclear solution, it was placed in sonication. DMAP (0.051 g) was added to the unclear solution. Lastly the mixture was put into swollen resins and shaken for more than an hour. For the rest of amide couplings, CS336X peptide synthesizer (CS Bio, Menlo Park, USA) was used. After finishing synthesis, peptides were well cleaved from resin in 95% TFA (9552.552.5 TFA/Anisole/TIS, v/v/v) within two hours. Using rotary evaporator, TFA was evaporated. Cold anhydrous ether (stored in 220uC) was added and centrifuged at 3000 rpm for 10 minutes twice. Finally, precipitated white powder was isolated, dissolved in 50% acetonitrile, lyophilized and purified using reverse-phase HPLC as previously reported 22 .
Animals . In detail, we used a Hamilton syringe with a 26-gauge stainless-steel needle to inject the Ab(1-42) stocks into the ICV region by 1.0 mm posterior to bregma, 1.8 mm lateral to saggital, 3.6 mm ventral and 2.4 mm depth.
Spontaneous alternation Y-maze after ICV injection Ab(1-42). Subjected mice (n 5 7 per group) received 0.25 nmole of Ab(1-42) via ICV injection. The Y-maze task was carried out four days after Ab(1-42) injection. This maze was composed of black painted wood; each arm was 40 cm long, 12 cm high, 3 cm wide at the bottom and 10 cm wide at the top. The arms converged at an equilateral triangular central area that was 4 cm at its longest axis. Each mouse was placed at one arm area, and allowed to move freely through the maze during eight minutes. Alternation was defined a successive entry into the arms, on overlapping triplet sets. The alternation behavior (%) was calculated as alternation behavior % ð Þ~actual alternations ð Þ = possible alternations ð Þ |100
CSF and plasma collection. Considering that the half-time of Ab(1-40) efflux from the CSF to blood, of C57BL/6, was previously measured as 34.63 6 3.6 minutes 18 , we collected CSF and plasma 30 minutes after the ICV injection. CSF sampling was performed according to the method described previously 25 . Anesthetized mice were placed prone, and their cisterna magna were surgically exposed. The exposed meninges were penetrated with laboratory-produced capillary tube that had a tapered tip and obtained CSF. After CSF collection, the mice were placed supine, and their trunks were surgically opened. Blood collected from the vena cava was transferred to EDTA tube with protease inhibitor cocktail (Roche Diagnostics, cat# 11836170001) and shaken gently. Plasma was separated from EDTA treated blood. Collected CSF and plasma samples were frozen immediately on dry ice and then stored at 280uC freezer.
Ab(1-42) analyzed by sandwich-ELISA in mouse CSF and plasma. Levels of Ab(1-42) in CSF were quantified by using the Human Ab42 Ultrasensitive ELISA kit (Invitrogen, cat# KHB3544). Limit of detection of the kit is , 1.0 pg/mL. We added the protease inhibitor cocktail into the standard diluent buffer from the kit and, then, used the mixture to dilute the collected CSF samples to 100 or 400 folds depending on the amounts of ICV-injected Ab(1-42): 0, 0.25 and 0.5 nmole of Ab(1-42) to 100 folds and 2 and 4 nmole of Ab(1-42) to 400 folds. The sandwich-ELISA was performed according to the manufacturer's instructions using the diluted samples. Briefly, we added diluted CSF into the 96-well plates coated with anti-Ab (N-term) monoclonal antibody, and co-incubated with additional C-term targeting anti-Ab(1-42) monoclonal antibody (rabbit) (3 hours) at RT. Then, we incubated the samples with horseradish peroxidase (HRP)-conjugated anti-rabbit antibody (30 minutes) at RT followed by the stabilized chromogen reagent. After addition of stop solution, we measured absorbance intensity at 450 nm to detect the amount of Ab(1-42) in each sample. The concentration range of Ab(1-42) standards was 0 to 100 pg/mL (8 points: 0, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100 pg/mL). The data processing to obtain the concentration of Ab(1-42) was based on the standard curve (R 2 5 0.995, %relative error 5 7.658%).
Levels of Ab(1-42) in plasma were quantified by using the Human Ab42 Ultrasensitive ELISA kit (Invitrogen, cat# KHB3544). Limit of detection of the kit is , 1.0 pg/mL. We diluted the collected plasma samples to 100 or 1,000 folds depending on the amounts of ICV-injected Ab(1-42): 0, 0.25 and 0.5 nmole of Ab(1-42) to 100 folds and 2 and 4 nmole of Ab(1-42) to 1,000 folds. The sandwich-ELISA was performed according to the manufacturer's instructions using the diluted samples. The detail is identical to the aforementioned method measuring CSF Ab (1-42) . The concentration range of Ab(1-42) standards was 0 to 100 pg/mL (8 points: 0, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100 pg/mL).The data processing to obtain the concentration of Ab(1-42) was based on the standard curve (R 2 5 0.996, %relative error 5 11.824%).
Statistical analysis. Ab(1-42) concentrations were expressed as mean 6 SD. Statistical analysis was performed with Graphpad Prism software (Graphpad Software, CA, USA). Significance was determined by using Student's t-test and Kruskal-Wallis test, followed by Dunn's post hoc tests for comparisons between vehicle control and treated samples.
All experimental protocols were approved by Korea Institute of Science and Technology and Institutional Animal Care and Use Committee of Korea Institute of Science and Technology (AP-2011L1015).
